ATLANTA, Jan. 26, 2026 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) complied with federal securities laws. On January 8, 2026, Beta Bionics announced preliminary, unaudited fourth quarter 2025 topline financial results, reporting that new patient starts, or the total number of individuals who have initiated use of the iLet Bionic Pancreas System, are expected to be below analyst estimates for the fourth quarter. Following this news, the price of the Company’s stock dropped.
If you purchased Beta Bionics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/beta-bionics/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025 dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
